Duchenne Muscular Dystrophy Pipeline Review, H1 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Duchenne Muscular Dystrophy - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Duchenne Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Duchenne Muscular Dystrophy Overview
  3. Therapeutics Development
  4. Pipeline Products for Duchenne Muscular Dystrophy - Overview
  5. Pipeline Products for Duchenne Muscular Dystrophy - Comparative Analysis
  6. Duchenne Muscular Dystrophy - Therapeutics under Development by Companies
  7. Duchenne Muscular Dystrophy - Therapeutics under Investigation by Universities/Institutes
  8. Duchenne Muscular Dystrophy Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Duchenne Muscular Dystrophy - Products under Development by Companies
  13. Duchenne Muscular Dystrophy - Products under Investigation by Universities/Institutes
  14. Duchenne Muscular Dystrophy - Companies Involved in Therapeutics Development
  • Acceleron Pharma, Inc.
  • Anagenesis Biotechnology
  • Asklepios BioPharmaceutical, Inc.
  • Bamboo Therapeutics, Inc.
  • BioMarin Pharmaceutical Inc.
  • Bristol-Myers Squibb Company
  • Capricor Therapeutics, Inc.
  • Catabasis Pharmaceuticals, Inc.
  • Daiichi Sankyo Company, Limited
  • Debiopharm International S.A.
  • Editas Medicine, Inc.
  • Eli Lilly and Company
  • EryDel SPA
  • FibroGen, Inc.
  • Galapagos NV
  • Genethon
  • GTx, Inc.
  • Idera Pharmaceuticals, Inc.
  • Italfarmaco S.p.A.
  • La Jolla Pharmaceutical Company
  • Marathon Pharmaceuticals, LLC
  • Marina Biotech, Inc.
  • Merck KGaA
  • Nippon Shinyaku Co., Ltd.
  • nLife Therapeutics, S.L.
  • Nobelpharma Co., Ltd.
  • Pfizer Inc.
  • Prothelia, Inc.
  • PTC Therapeutics, Inc.
  • Santhera Pharmaceuticals Holding AG
  • Sarepta Therapeutics, Inc.
  • Summit Therapeutics Plc
  • Taiho Pharmaceutical Co., Ltd.
  • WAVE Life Sciences Ltd.
  • Zambon Company S.p.A.

For more information visit http://www.researchandmarkets.com/research/f44h78/duchenne_muscular

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716